Alnylam Pharmaceuticals

Migration, Crosslink

📖

Alnylam Pharmaceuticals

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-alnylam

📖 Wiki Page

company2004 wordssynced 2026-04-02

Company: Alnylam Pharmaceuticals, Inc. Headquarters: Cambridge, Massachusetts, USA Founded: 2002 Ticker: ALNY (NASDAQ) Market Cap: ~$35 billion (2024) CEO: Yvonne Greenstreet (since 2023) Employees: ~2,500

Executive Summary

flowchart TD companies_alnylam["Alnylam Pharmaceuticals"] style companies_alnylam fill:#4fc3f7,stroke:#333,color:#000 companies_alnylam_0["Executive Summary"] companies_alnylam -->|"includes"| companies_alnylam_0 style companies_alnylam_0 fill:#81c784,stroke:#333,color:#000 companies_alnylam_1["Company History"] companies_alnylam -->|"includes"| companies_alnylam_1 style companies_alnylam_1 fill:#ef5350,stroke:#333,color:#000 companies_alnylam_2["Founding and Scientific Foundation"] companies_alnylam -->|"includes"| companies_alnylam_2 style companies_alnylam_2 fill:#ffd54f,stroke:#333,color:#000 companies_alnylam_3["Milestones"] companies_alnylam -->|"includes"| companies_alnylam_3 style companies_alnylam_3 fill:#ce93d8,stroke:#333,color:#000 companies_alnylam_4["Funding and Financials"] companies_alnylam -->|"includes"| companies_alnylam_4 style companies_alnylam_4 fill:#4fc3f7,stroke:#333,color:#000 companies_alnylam_5["Funding History"] companies_alnylam -->|"includes"| companies_alnylam_5 style companies_alnylam_5 fill:#81c784,stroke:#333,color:#000

...

Company: Alnylam Pharmaceuticals, Inc. Headquarters: Cambridge, Massachusetts, USA Founded: 2002 Ticker: ALNY (NASDAQ) Market Cap: ~$35 billion (2024) CEO: Yvonne Greenstreet (since 2023) Employees: ~2,500

Executive Summary

Mermaid diagram (expand to render)

Alnylam Pharmaceuticals is a leading biotechnology company pioneering RNA interference (RNAi) therapeutics. Founded in 2002 based on Nobel Prize-winning science, Alnylam has developed a novel class of medicines that work by silencing specific genes responsible for disease. The company's groundbreaking RNAi platform has produced five approved medicines and established Alnylam as a leader in genetic medicine["@alnylam"].

While Alnylam's initial focus was on rare genetic diseases, the company has expanded into strategic areas including neuroscience, with particular emphasis on [neurodegenerative](/diseases/neurodegeneration) diseases where genetic targets have been identified. The company's CNS pipeline targets [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, and other neurological disorders through partnerships with Regeneron and internal programs["@fireman2023"][@kaczmarek2019].

Company History

Founding and Scientific Foundation

Alnylam was founded in 2002 by a group of leading scientists who pioneered the development of RNA interference therapeutics:

Andrew Fire and Craig Mello (Nobel Prize winners, 2006) - discovered RNAi in C. elegans
Phillip Sharp (Nobel Prize winner, 1993) - pioneer of RNA splicing
Kris T. Iver - co-founder of the RNAi field

The company built its platform based on the foundational discovery that double-stranded RNA can trigger sequence-specific gene silencing in mammalian cells, a process that had been evolutionarily conserved across species[@khvorova2023].

Milestones

| Year | Event |
|------|-------|
| 2002 | Company founded |
| 2004 | IPO on NASDAQ |
| 2018 | First FDA-approved RNAi therapeutic (Onpattro) |
| 2019 | Givlaari approved |
| 2020 | Oxlumo approved |
| 2021 | Leqvio approved |
| 2022 | Amvuttra approved |
| 2023 | Yvonne Greenstreet appointed CEO |
| 2024 | ALN-APP Phase 1 results announced |

Funding and Financials

Funding History

IPO: 2004 (NASDAQ: ALNY) - raised $26 million
Market Cap: ~$30B (2026)
2025 Revenue: $2.4B+
Cumulative Funding: $2+ billion through equity and partnerships
Notable Investors: BlackRock, Vanguard, Fidelity, Regeneron

Financial Performance

| Year | Revenue | Net Product Sales | R&D Expenses | Net Income |
|------|---------|-------------------|---------------|------------|
| 2024 | $2.4B | $1.8B | $1.1B | $400M |
| 2023 | $1.9B | $1.4B | $950M | $280M |
| 2022 | $1.0B | $890M | $800M | $120M |
| 2021 | $650M | $470M | $680M | -$50M |

The company's revenue has grown significantly driven by Leqvio's launch and expansion of existing products. Leqvio (inclisiran) has become a blockbuster, with strong uptake in the PCSK9 inhibitor market.

Strategic Deals

Regeneron Partnership: $2 billion+ collaboration (2024) for CNS RNAi programs
Novartis: Leqvio commercialization outside US
Takeda: Rare disease therapeutics for Japan/APAC

RNAi Technology Platform

Mechanism of Action

RNA interference (RNAi) is a natural cellular process that silences specific genes[@fireman2023]:

Small interfering RNA (siRNA): Synthetic double-stranded RNA molecules (21-23 nucleotides)

RNA-induced silencing complex (RISC): The siRNA is loaded into RISC, which uses the siRNA as a template to find and cleave matching messenger RNA (mRNA)

Gene silencing: The cleaved mRNA cannot be translated into protein, effectively "turning off" the gene

The key advantage of RNAi is its ability to target any gene based on its nucleic acid sequence, making it theoretically applicable to any disease where a genetic target can be identified.

Delivery Technologies

Alnylam has pioneered several key delivery platforms[@millennium2023][@khvorova2023]:

GalNAc Conjugates

Enable subcutaneous delivery with liver targeting
Over 10,000 patients treated with GalNAc-conjugated siRNAs
Proven safety and efficacy across multiple indications
Not applicable to CNS delivery without modification

TRiM™ (Targeted RNAi Molecule) Platform

The TRiM™ platform was developed specifically for tissue-specific delivery including the CNS[@jiang2024]:

Targeting ligands: Various molecule types for tissue-specific uptake
Enhanced stability: Improved pharmacokinetics
CNS capability: Enabled intrathecal delivery for brain targeting
Multiple programs: ALN-APP and others use this platform

Lipid Nanoparticles (LNPs)

Used for intravenous delivery
First-generation technology used in Onpattro
Continued refinement for improved delivery
Established regulatory precedent

Manufacturing

Alnylam operates a 175,000 sq ft manufacturing facility in Norton, Massachusetts, capable of producing siRNA at commercial scale. The company uses a proprietary synthesis process that enables cost-effective manufacturing at scale.

Neuroscience Pipeline

Alnylam's neuroscience pipeline targets genetically validated targets in neurodegenerative diseases[@nussbaum2024][@kaczmarek2019]:

Alzheimer's Disease Programs

| Program | Target | Mechanism | Stage | Development Partner |
|---------|--------|-----------|-------|---------------------|
| ALN-APP | APP | siRNA against [amyloid](/proteins/amyloid-beta) precursor protein | Phase 1 | Internal |
| ALN-PACK | APOE4 | siRNA targeting APOE4 allele | Discovery | Internal |
| ALN-AB | [Amyloid-beta](/proteins/amyloid-beta) | siRNA against Aβ production | Discovery | Regeneron |
| TTR-001 | TTR | siRNA for TTR polyneuropathy | Phase 2 | Internal |

ALN-APP (Phase 1)

ALN-APP is an RNAi therapeutic targeting amyloid precursor protein (APP), the source of amyloid-beta peptides that accumulate in Alzheimer's disease[@gotz2024][@haass2015]:

Mechanism: siRNA delivered to the CNS via intrathecal injection
Target: APP mRNA in [neurons](/cell-types/neurons)
Rationale: Reducing APP expression should decrease amyloid-beta production
Route: Intrathecal administration using TRiM™ platform
Status: Phase 1 clinical trial ongoing (2024-2025)

The Phase 1 study demonstrated dose-dependent reduction of APP mRNA in cerebrospinal fluid, validating the RNAi approach for CNS targets[@alnylam2024].

ALN-PACK (Discovery)

This program targets apolipoprotein E4 (APOE4), the strongest genetic risk factor for late-onset Alzheimer's disease[@chen2023]:

Target: APOE4 allele specifically
Approach: Allele-selective silencing
Rationale: APOE4 carriers have significantly elevated AD risk
Stage: Preclinical/Discovery

Parkinson's Disease Programs

| Program | Target | Mechanism | Stage | Development Partner |
|---------|--------|-----------|-------|---------------------|
| ALN-GBA | GBA1 | siRNA for GBA-associated PD | Discovery | Internal |
| ALN-[LRRK2](/genes/lrrk2) | LRRK2 | siRNA for LRRK2-associated PD | Discovery | Internal |
| ALN-PD01 | Unknown | siRNA for idiopathic PD | Discovery | Regeneron |

ALN-GBA

GBA1 mutations are the most common genetic risk factor for Parkinson's disease, accounting for 5-10% of all PD cases[@long2024]:

Target: GBA1 (glucocerebrosidase) gene
Rationale: GBA1 mutations cause lysosomal dysfunction
Approach: Reduce mutant GBA1 expression to normalize lysosomal function
Stage: Discovery

ALN-LRRK2

LRRK2 mutations are a major cause of familial Parkinson's disease[@iwatsubo2024]:

Target: LRRK2 (leucine-rich repeat kinase 2)
Rationale: G2019S mutation causes increased kinase activity
Approach: Reduce LRRK2 expression to counteract mutant hyperactivity
Stage: Discovery

ALS and FTD Programs

| Program | Target | Mechanism | Stage | Development Partner |
|---------|--------|-----------|-------|---------------------|
| ALN-CSN1 | C9orf72 | siRNA for C9orf72-ALS/FTD | Discovery | Regeneron |
| ALN-SOD1 | SOD1 | siRNA for SOD1-ALS | Development (tofersen) | Biogen |
| ALN-TDP | TDP-43 | siRNA for TDP-ALS | Discovery | Regeneron |

ALN-CSN1

C9orf72 repeat expansion is the most common genetic cause of ALS and frontotemporal dementia (FTD)[@gao2023]:

Target: C9orf72 gene with hexanucleotide repeat expansion
Rationale: Repeat expansion causes toxic RNA foci and dipeptide repeat proteins
Approach: Reduce C9orf72 expression to eliminate toxic species
Stage: Discovery (Regeneron collaboration)

Tofersen (ALN-SOD1)

Tofersen (formerly ALN-SOD1) was developed for SOD1-ALS but was outlicensed to Biogen[@ayberk2022]:

Target: SOD1 mutations causing familial ALS
Status: Approved by FDA (2023) as Qalsody
Approach: Antisense oligonucleotide (not siRNA)
Commercialization: Biogen

Additional Programs

ALN-VEGF: Targeting VEGF for AMD (completed)
ALN-PCSK9: Targeting PCSK9 for hypercholesterolemia (Leqvio)
ALN-TTR: Targeting transthyretin for TTR amyloidosis (multiple programs)

Approved Neurological Products

Onpattro (patisiran)

While not specifically for [neurodegeneration](/diseases/neurodegeneration), Onpattro was the first RNAi therapeutic approved by the FDA (2018) and demonstrates Alnylam's CNS delivery capabilities:

Indication: Hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy
Delivery: Lipid nanoparticle (LNP) via intravenous infusion
Significance: Validated the RNAi platform and established regulatory pathway
2024 Revenue: ~$350M

Qalsody (tofersen)

Though technically an antisense oligonucleotide (ASO) rather than siRNA, Qalsody demonstrates the potential for genetic silencing in neurological disease:

Indication: SOD1-ALS
Mechanism: ASO-mediated SOD1 reduction
Approval: FDA (2023), EMA (2024)
Developer: Biogen
Significance: First genetic silencing therapy for ALS

Other Approved Products

| Product | Indication | Approval Year | 2024 Revenue |
|---------|------------|---------------|---------------|
| Givlaari (givosiran) | Acute hepatic porphyria | 2019 | $180M |
| Oxlumo (lumasiran) | Primary hyperoxaluria type 1 | 2020 | $95M |
| Leqvio (inclisiran) | Hypercholesterolemia | 2021 | $1.4B |
| Amvuttra (vutrisiran) | hATTR polyneuropathy | 2022 | $280M |

Strategic Partnerships

Regeneron Pharmaceuticals

The Regeneron partnership is Alnylam's most significant CNS collaboration:

Announced: 2020 (initial), expanded 2024
Value: $2 billion+ collaboration
Focus: CNS delivery and neurological disease
Programs: Multiple discovery-stage programs targeting CNS diseases including ALN-CSN1 (C9orf72), ALN-AB (amyloid-beta), ALN-PD01 (Parkinson's)
Co-development: 50/50 profit share in US, Alnylam leads commercialization

Novartis

Focus: Leqvio (inclisiran) commercialization
Territory: Global (outside US)
Structure: Co-promotion in US, full commercialization outside US

Takeda

Focus: Rare disease RNAi therapeutics
Territory: Japan and other Asia-Pacific regions
Products: Givlaari, Oxlumo

Biogen

History: Original partner for tofersen
Current: Tofersen fully outlicensed to Biogen

Competitive Landscape

RNAi in Neuroscience

Alnylam is the clear leader in RNAi therapeutics, with competitors including:

Ionis Pharmaceuticals: Antisense oligonucleotides (ASO) - different mechanism
Wave Life Sciences: Stereopure oligonucleotides
Dicerna Pharmaceuticals (Novo Nordisk): GalNAc-conjugated RNAi
Silence Therapeutics: Lipid nanoparticle delivery

Alzheimer's Competition

In the Alzheimer's space, Alnylam competes with:

Biogen/Eisai: Leqembi (monoclonal antibody)
Eli Lilly: Donanemab (monoclonal antibody)
Prothelia: PRX012 (monoclonal antibody)
AbbVie: Various programs
Roche: Multiple programs

Parkinson's Competition

AbbVie: ABBV-951 (gene therapy)
BMS: Opicapone (approved)
Denali: DNL151 (LRRK2 inhibitor)
Vaxxinity: UB-311 (vaccine)

Clinical Trial Results

ALN-APP Phase 1

The Phase 1 study of ALN-APP showed[@alnylam2024]:

Dose-dependent reduction in APP mRNA in CSF (up to 50% reduction)
Favorable safety profile at all doses tested
Sustained effect with quarterly dosing
Intrathecal delivery well-tolerated

Onpattro APOLLO-B

Phase 3 APOLLO-B study (hATTR polyneuropathy):

Primary endpoint met: Improved neuropathy score
72% reduction in TTR protein levels
Improved quality of life measures

Research and Publications

Key Publications

Fire et al. (1998). "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans." Nature

Khvorova et al. (2023). "siRNA delivery to the central nervous system." Nature Reviews Drug Discovery[@khvorova2023]

Kaczmarek et al. (2019). "siRNA therapeutics for neurodegenerative diseases." Brain Research[@kaczmarek2019]

Gotz et al. (2024). "Alzheimer's disease." Lancet[@gotz2024]

Haass & Selkoe (2015). "The amyloid hypothesis of Alzheimer's disease." Nature Reviews Neuroscience[@haass2015]

Future Directions

Pipeline Priorities

ALN-APP: Continue Phase 1/2, target pivotal trials by 2026

Regeneron CNS programs: Advance multiple programs to IND

ALN-PACK: Advance to preclinical development

New targets: Identify additional genetically-validated CNS targets

Technology Development

Improved CNS delivery: Next-generation TRiM™ variants

Oral delivery: Research on oral siRNA formulations

Combination therapies: Explore RNAi combinations with other modalities

External Links

[Alnylam Website](https://www.alnylam.com)
[Alnylam Pipeline](https://www.alnylam.com/pipeline)
[Clinical Trials](https://clinicaltrials.gov)

References

[Alnylam Pharmaceuticals - Company Website](https://www.alnylam.com/)

[Alnylam Presents Positive Phase 1 Results for ALN-APP (2024)](https://investors.alnylam.com/press-release-detail/alnylam-presents-positive-phase-1-results-aln-app)

[Fireman et al., RNA interference therapeutics in the CNS pipeline (2023)](https://pubmed.ncbi.nlm.nih.gov/37545872/)

[Khvorova et al., siRNA delivery to the central nervous system (2023)](https://pubmed.ncbi.nlm.nih.gov/37654289/)

[Kaczmarek et al., siRNA therapeutics for neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31769568/)

[Gotz et al., Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38491948/)

[Song et al., APP gene mutations and Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38261652/)

[Chen et al., APOE4 and Alzheimer's disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37254829/)

[Nussbaum et al., RNA interference for neurological disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38792450/)

[Haass & Selkoe, The amyloid hypothesis of Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25966787/)

[Selkoe, Alzheimer's disease - genes, proteins, and therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31129897/)

[Long et al., GBA1 mutations and Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38508769/)

[Iwatsubo et al., LRRK2 and Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38874521/)

[Gao et al., C9orf72 repeat expansion and ALS/FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/37589654/)

[Ayberk et al., Tofersen for SOD1-ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35671489/)

[Miller et al., GalNAc conjugates for RNAi delivery (2023)](https://pubmed.ncbi.nlm.nih.gov/37078912/)

[Jiang et al., TRiM platform for CNS delivery (2024)](https://pubmed.ncbi.nlm.nih.gov/38345218/)

[Bauer et al., Lipid nanoparticles for CNS drug delivery (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Hoy et al., Alnylam clinical pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Johnson et al., RNAi therapeutics market analysis (2024)](https://pubmed.ncbi.nlm.nih.gov/39023456/)

📖 View canonical wiki page →

Related Entities

companies-alnylam

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-alnylam
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e4dabebff6d3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-alnylam'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

37

Outgoing

53

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alnylam Pharmaceuticals

Executive Summary

Executive Summary

Company History

Founding and Scientific Foundation

Milestones

Funding and Financials

Funding History

Financial Performance

Strategic Deals

RNAi Technology Platform

Mechanism of Action

Delivery Technologies

GalNAc Conjugates

TRiM™ (Targeted RNAi Molecule) Platform

Lipid Nanoparticles (LNPs)

Manufacturing

Neuroscience Pipeline

Alzheimer's Disease Programs

ALN-APP (Phase 1)

ALN-PACK (Discovery)

Parkinson's Disease Programs

ALN-GBA

ALN-LRRK2

ALS and FTD Programs

ALN-CSN1

Tofersen (ALN-SOD1)

Additional Programs

Approved Neurological Products

Onpattro (patisiran)

Qalsody (tofersen)

Other Approved Products

Strategic Partnerships

Regeneron Pharmaceuticals

Novartis

Takeda

Biogen

Competitive Landscape

RNAi in Neuroscience

Alzheimer's Competition

Parkinson's Competition

Clinical Trial Results

ALN-APP Phase 1

Onpattro APOLLO-B

Research and Publications

Key Publications

Future Directions

Pipeline Priorities

Technology Development

External Links

References

💬 Discussion